Rockingstone Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.19M Buy
3,617
+5
+0.1% +$5.9K 1.68% 20
2026
Q2
$4.33M Buy
3,612
+112
+3% +$114K 1.74% 21
2026
Q1
$3.22M Sell
3,500
-2
-0.1% -$2.03K 1.48% 27
2025
Q4
$3.76M Buy
3,502
+452
+15% +$432K 1.71% 20
2025
Q3
$2.33M Buy
3,050
+357
+13% +$266K 1.15% 35
2025
Q2
$2.1M Sell
2,693
-1,030
-28% -$800K 1.1% 39
2025
Q1
$3.07M Buy
3,723
+635
+21% +$528K 1.38% 30
2024
Q4
$2.38M Buy
3,088
+2,783
+912% +$2.3M 1.05% 37
2024
Q3
$270K Buy
305
+60
+24% +$53.9K 0.13% 90
2024
Q2
$222K Buy
+245
New +$196K 0.11% 101
2023
Q4
– Sell
-475
Closed -$255K – 117
2023
Q3
$255K Buy
+475
New +$245K 0.14% 106

Other funds holding LLY

Rockingstone Advisors's LLY Position: Q3 2026 in Review

Rockingstone Advisors increased its Eli Lilly (LLY) stake by 0.14% in Q3 2026, buying an estimated $5.9K and bringing the position to 3,617 shares worth $4.19M. The position accounts for 1.68% of the portfolio, ranked #20.

Rockingstone Advisors first reported a position in LLY in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.33M in Q2 2026. 2,227 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Rockingstone Advisors held 3,617 shares of Eli Lilly worth $4.19M as of Q3 2026.
  • Rockingstone Advisors bought 5 Eli Lilly shares in Q3 2026, an estimated $5.9K.
  • Eli Lilly made up 1.68% of Rockingstone Advisors's portfolio in Q3 2026, its #20 holding.
  • Rockingstone Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 11 quarters since.
  • Rockingstone Advisors's Eli Lilly position peaked at $4.33M in Q2 2026.
  • 2,227 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Rockingstone Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.